Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active γ-secretase modulators

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 8, 2012, Pages 2906-2911

  Pettersson, Martin ^a   Johnson, Douglas S ^a   Subramanyam, Chakrapani ^a   Bales, Kelly R ^a   Am Ende, Christopher W ^a   Fish, Benjamin A ^a   Green, Michael E ^a   Kauffman, Gregory W ^a   Lira, Ricardo ^a   Mullins, Patrick B ^a   Navaratnam, Thayalan ^a   Sakya, Subas M ^a   Stiff, Cory M ^a   Tran, Tuan P ^a   Vetelino, Beth C ^a   Xie, Longfei ^a   Zhang, Liming ^a   Pustilnik, Leslie R ^a   Wood, Kathleen M ^a   O'Donnell, Christopher J ^a  

^a PFIZER INC   (United States)

Author keywords

Secretase modulators; Alzheimer's disease

Indexed keywords

AMIDE; DIHYDROBENZOFURAN DERIVATIVE; GAMMA SECRETASE;

ANIMAL EXPERIMENT; ARTICLE; IN VITRO STUDY; NONHUMAN; PHYSICAL CHEMISTRY;

ADMINISTRATION, ORAL; AMIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BENZOFURANS; DRUG DESIGN; ENZYME ACTIVATION; ENZYME INHIBITORS; GUINEA PIGS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; PROTEIN BINDING; RATS;

EID: 84862805277     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2012.02.059     Document Type: Article

References (46)

1. A. Wimo, and M. Prince World Alzheimer Report 2010: The Global Economic Impact of Dementia 2010 Alzheimer's Disease International (ADI) London, U.K.
2. D.M. Walsh, and D.J. Selkoe J. Neurochem. 101 2007 1172
3. B. De Strooper, R. Vassar, and T. Golde Nat. Rev. Neurol. 6 2010 99
4. A. Haapasalo, and D.M. Kovacs J. Alzheimers Dis. 25 2011 3
5. U. Saxena Expert Opin. Ther. Targets 14 2010 273
6. B.P. Imbimbo, F. Panza, V. Frisardi, V. Solfrizzi, G. D'Onofrio, G. Logroscino, D. Seripa, and A. Pilotto Expert. Opin. Investig. Drugs 20 2011 325
7. X. Xia, S. Qian, S. Soriano, Y. Wu, A.M. Fletcher, X.J. Wang, E.H. Koo, X. Wu, and H. Zheng Proc. Natl. Acad. Sci. U.S.A. 98 2001 10863
8. N.F. Schor Ann. Neurol. 69 2011 237
9. M. Pettersson, G.W. Kauffman, C.W. am Ende, N.C. Patel, C. Stiff, T.P. Tran, and D.S. Johnson Expert Opin. Ther. Pat. 21 2011 205
10. D. Oehlrich, D.J.-C. Berthelot, and H.J.M. Gijsen J. Med. Chem. 54 2011 669
11. H. Zettl, S. Weggen, P. Schneider, and G. Schneider Trends Pharmacol. Sci. 31 2010 402
12. C.J. Crump, B.A. Fish, S.V. Castro, D.-M. Chau, N. Gertsik, K. Ahn, C. Stiff, N. Pozdnyakov, K.R. Bales, D.S. Johnson, and Y.-M. Li ACS Chem. Neurosci. 69 2011 705
13. Y. Ohki, T. Higo, K. Uemura, N. Shimada, S. Osawa, O. Berezovska, S. Yokoshima, T. Fukuyama, T. Tomita, and T. Iwatsubo EMBO J. 30 2011 4815
14. A. Ebke, T. Luebbers, A. Fukumori, K. Shirotani, C. Haass, K. Baumann, and H. Steiner J. Biol. Chem. 286 2011 37181
15. C.J. Crump, D.S. Johnson, and Y.-M. Li EMBO J. 30 2011 4696
16. E. Portelius, B. Van Broeck, U. Andreasson, M.K. Gustavsson, M. Mercken, H. Zetterberg, H. Borghys, and K. Blennow J. Alzheimers Dis. 1005 2010 21
17. For other strategies to replace the cinnamide moiety see: T. Lubbers, A. Flohr, S. Jolidon, P. David-Pierson, H. Jacobsen, L. Ozmen, and K. Baumann Bioorg. Med. Chem. Lett. 21 2011 6554
18. J. Qin, P. Dhondi, X. Huang, M. Mandal, Z. Zhao, D. Pissarnitski, W. Zhou, R. Aslanian, Z. Zhu, W. Greenlee, J. Clader, L. Zhang, M. Cohen-Williams, N. Jones, L. Hyde, and A. Palani Bioorg. Med. Chem. Lett. 21 2011 664
19. J.P. Caldwell, C.E. Bennett, T.M. McCracken, R.D. Mazzola, T. Bara, A. Buevich, D.A. Burnett, I. Chu, M. Cohen-Williams, H. Josein, L. Hyde, J. Lee, B. McKittrick, L. Song, G. Terracina, J. Voigt, L. Zhang, and Z. Zhu Bioorg. Med. Chem. Lett. 20 2010 5380
20. X. Huang, R. Aslanian, W. Zhou, X. Zhu, J. Qin, W. Greenlee, Z. Zhu, L. Zhang, L. Hyde, I. Chu, M. Cohen-Williams, and A. Palani ACS Med. Chem. Lett. 1 2010 184
21. J. Qin, W. Zhou, X. Huang, P. Dhondi, A. Palani, R. Aslanian, Z. Zhu, W. Greenlee, M. Cohen-Williams, N. Jones, L. Hyde, and L. Zhang ACS Med. Chem. Lett. 2 2011 471
22. Z.-Y. Sun, T. Asberom, T. Bara, C. Bennett, D. Burnett, I. Chu, J. Clader, M. Cohen-Williams, D. Cole, M. Czarniecki, J. Durkin, G. Gallo, W. Greenlee, H. Josien, X. Huang, L. Hyde, N. Jones, I. Kazakevich, H. Li, X. Liu, J. Lee, M. MacCoss, M.B. Mandal, T. McCracken, A. Nomeir, R. Mazzola, A. Palani, E.M. Parker, D.A. Pissarnitski, J. Qin, L. Song, G. Terracina, M. Vicarel, J. Voigt, R. Xu, L. Zhang, Q. Zhang, Z. Zhao, X. Zhu, and Z. Zhu J. Med. Chem. 55 2012 489
23. In general, oral drugs tend to have a LipE between 5 and 7; see: P.D. Leeson, and B. Springthorpe Nat. Rev. Drug Disc. 6 2007 881
24. Log D at pH 7.4 calculated using ACD version 9.03.
25. T.T. Wager, R.Y. Chandrasekaran, X. Hou, M.D. Troutman, P.R. Verhoest, A. Villalobos, and T. Will ACS Chem. Neurosci. 1 2010 420
26. An analysis of a set of CNS drugs (N = 119) showed that 74% have a CNS MPO score ≥4 on a scale of 0-6: see: T.T. Wager, X. Hou, P.R. Verhoest, and A. Villalobos ACS Chem. Neurosci. 1 2010 435
27. J.D. Hughes, J. Blagg, D.A. Price, S. Bailey, G.A. DeCrescenzo, R.V. Devraj, E. Ellsworth, Y.M. Fobian, M.E. Gibbs, R.W. Gilles, N. Greene, E. Huang, T. Krieger-Burke, J. Loesel, T. Wager, L. Whiteley, and Y. Zhang Bioorg. Med. Chem. Lett. 18 2008 4872
28. A hydrogen bond acceptor in the form of an amide, lactam, or various heterocycles in this region of the molecule is present in the majority of non-NSAID GSMs throughout the patent literature (see Ref. 6a,b).
29. Pfizer, Inc. WO10100606, 2010.
30. Pfizer, Inc. WO11048525, 2011.
31. Novartis AG, WO 11130379, 2011.
32. B. Sreedhar, G.T. Venkanna, K.B.S. Kumar, and V. Balasubrahmanyam Synthesis 5 2008 795
33. Eisai R&D Management Co., Ltd. US090062529, 2009.
34. A.F. Stepan, K. Karki, W.S. McDonald, P.H. Dorff, J.K. Dutra, K.J. DiRico, A. Won, C. Subramanyam, I.V. Efremov, C.J. O'Donnell, C.E. Nolan, S.L. Becker, L.R. Pustilnik, B. Sneed, H. Sun, Y. Lu, A.E. Robshaw, D. Riddell, T.J. O'Sullivan, E. Sibley, S. Capetta, K. Atchison, A.J. Hallgren, E. Miller, A. Wood, and R.S. Obach J. Med. Chem. 54 2011 7772
35. Assay method adapted from published protocols: R.J. Riley, D.F. McGinnity, and R.P. Austin Drug Metab. Dispos. 33 2005 1304
36. R.S. Obach Drug Metab. Dispos. 27 1999 1350
37. B. Feng, J.B. Mills, R.E. Davidson, R.J. Mireles, J.S. Janiszewski, M.D. Troutman, and S.M. de Morais Drug Metab. Dispos. 36 2008 268
38. A compound with a MDR efflux ratio (MDR Er) less than 2.5 is considered to have minimal P-gp efflux liability.
39. Values for c log P were calculated using the BIOBYTE (www.biobyte.com) program c log P, version 4.3.
40. TorreyPines Therapeutics, Inc.WO08137102, 2008. The compound from this patent application that inspired the synthesis of 33 is shown below
41. For the original report concerning the dihydrobenzofuranol synthesis see: B. Holt, and P.A. Lowe Tetrahedron Lett. 7 1966 683
42. For the Corey-Chaykovsky reagent see: E.J. Corey, and M. Chaykovsky J. Am. Chem. Soc. 84 1962 867
43. E.J. Corey, and M. Chaykovsky J. Am. Chem. Soc. 87 1965 1353
44. Single enantiomers were obtained by chiral separation of amines 30 or following the final amide coupling.
45. Male Hartley guinea pigs, weighing 200-250 g were administered vehicle or GSM 35 or 43 100 mg/kg orally. Brain, CSF and plasma were sampled at 4 h post-dose. Brains were homogenized in 0.4%DEA/50 mM NaCl, incubated overnight at 4 °C, then centrifuged at 135,000g for 1 h. Supernatant was collected for analysis. Plasma was incubated overnight with 5 M GuHCl. The DELFIA method was used to measure total Aβ1-x, Aβx-42, Aβx-40 and Aβ1-38 in brain supernatant, CSF and Plasma. CSF was diluted directly in assay buffer. Brain extracts and GuHCl-plasma were run over solid-phase extraction to remove nonspecific signal and concentrate.
46. u = 0.0097.